SKYE - התחייבויות לטווח ארוך של החברה Skye Bioscience, Inc.

Skye Bioscience, Inc. (SKYE) brings together leading biologists to develop unique vision therapies. The business model relies on outsourcing early-stage trials to third-party laboratories while maintaining strict control over patents. The share price history with the 0.00 metric illustrates the dynamics of the company, which is researching the endocannabinoid system to treat obesity and attracting talent through a stock option system and the high significance of its medical niche.

This indicator aggregates all credit obligations of Skye Bioscience, Inc. (SKYE) with a maturity exceeding one year. Monitoring this metric allows for an assessment of capital stability and the risk of asset devaluation due to excessive debt load. To develop unique glaucoma medications, borrowings may serve as leverage to accelerate research. By analyzing changes in the company's long-term debt, an investor can determine whether the development strategy remains balanced.